Skip to main content
BBLG logo
BBLG
(NASDAQ)
Bone Biologics Corporation
$1.26-- (--)
Loading... - Market loading

Bone Biologics (BBLG) Company Profile

Complete business overview, executive team, trading details, and corporate information.

Bone Biologics Corporation
BBLGNasdaq Stock MarketHealthcareBiotechnology

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Company Information

CEOJeffrey Frelick
Founded2004
Employees2
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone781 552 4452
Address
2 Burlington Woods Drive, Suite 100 Burlington, Massachusetts 01803 United States

Corporate Identifiers

CIK0001419554
CUSIP098070600
ISINUS0980706008
EIN42-1743430
SIC3842

Leadership Team & Key Executives

Jeffrey Frelick
Chief Executive Officer and President
Deina H. Walsh CPA
Chief Financial Officer